This inventor holds 1 USPTO granted patent and 1 published patent application and 1 EPO patent. Top assignee: Aventis Pharma S.a.. Active years: 2005.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
Company Filing History:
Years Active: 2005
Title: Innovations in Gene Therapy: The Contributions of Jean-Francois Dedieu
Introduction
Jean-Francois Dedieu is a notable inventor based in Paris, France. He has made significant contributions to the field of gene therapy, particularly through his innovative work on adenovirus vectors. His research focuses on the modification of adenovirus proteins to enhance the delivery of therapeutic genes.
Latest Patents
Dedieu holds a patent titled "Targeted adenovirus vectors for delivery of heterologous genes." This patent describes a method for modifying internal sites of the adenovirus fiber protein and hexon protein to allow for effective targeting of adenovirus vectors. The research identifies accessible sites for redirecting adenovirus targeting, specifically highlighting the HVR5 loop of the hexon protein and the HI loop of the fiber protein. These modifications do not adversely affect the viability and productivity of the corresponding viruses. The findings suggest that short targeting peptides can be effectively fused to the C-terminus of the fiber protein, which is particularly useful for targeting cells bearing the urokinase-type plasminogen activator receptor. Such vectors have promising applications in gene therapy for cancers and cardiovascular conditions.
Career Highlights
Jean-Francois Dedieu is associated with Aventis Pharma S.A., where he has been instrumental in advancing research in gene therapy. His work has contributed to the understanding of adenovirus vector modifications and their potential therapeutic applications.
Collaborations
Dedieu has collaborated with notable colleagues, including Emmanuelle Vigne and Martine Latta. Their combined efforts have furthered research in the field of gene therapy and adenovirus vector technology.
Conclusion
Jean-Francois Dedieu's innovative work in the modification of adenovirus vectors represents a significant advancement in gene therapy. His contributions have the potential to improve therapeutic strategies for various medical conditions.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile